Search
I4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read morePublications
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld…
EHA European Hematology Exam 2018 Report
1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.
Registration & accommodation
Registration is closed
Individual RegistrationHybrid registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks on November 2-4 and lunches on November 3 and 4
Access to…
EHA Research Mobility Grants
The call for applications is now open
EHA strives to develop the career of young scientists by supporting mobility and facilitating a visit to a research group in another institute.
Young EHA Committee
Current committee members
Nuno Borges, United Kingdom (Chair)
Alba Maiques Diaz, Spain (Vice-Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Franziska Auer, USA/Germany
Anna Avagyan, Armenia
Côme Bommier, France
Lorenzo Brunetti, Italy
Eleni Gavriilaki, Greece
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Pedro Moura, Sweden
Rhiannon Newman, Finland
Marlies Vanden Bempt, Belgium
Carlo Zaninetti, Germany
AimYoung…
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).